Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Press releaseGlobeNewswire· February 19, 2026

NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform

NovaBridge Appoints Biotech Leader, Emmett T…

Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet AMD and DME
80% confidence
VIS-101 is a second-in-class, potentially best-in-class bifunctional biologic targeting VEGF-A and ANG2
80% confidence
NovaBridge's unique global biotech platform has potential to bridge the gap between unmet patient needs and transformative care
80% confidence
Dr. Cunningham's distinguished career as a physician and proven entrepreneur, combined with his expertise in accelerating early-stage programs across several therapeutic areas, perfectly complements NovaBridge's unique hub-and-spoke business model
80% confidence
Givastomig is a potential best-in-class, Claudin 18.2 x 4-1BB bispecific antibody
80% confidence